Who
Amit Sachdev
EVP Chief Patient & Ext Af Off
Company insider
Files Form 4 as: EVP Chief Patient & Ext Af Off, Vertex Pharmaceuticals; Director, Eiger BioPharmaceuticals.
In numbers
- Trades disclosed
- 528
- Buys
- 1
- Sells
- 105
- Bought
- $25K
- Sold
- $203.9M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 23 Jul 2007
- Last trade
- 21 Jul 2026
- Last filed
- 23 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Jul 2026filed 23 Jul 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —8,251 at $0.00 | filing |
| 21 Jul 2026filed 23 Jul 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —8,251 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $898K1,846 at $486.35 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $898K1,846 at $486.35 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $736K1,518 at $485.11 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $736K1,518 at $485.11 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3.7M23,479 at $155.57 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.0M4,237 at $471.43 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,479 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,026 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $4.7M25,026 at $187.53 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $427K920 at $463.91 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,479 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,026 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.3M2,730 at $465.05 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $861K1,848 at $465.80 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4.8M10,263 at $467.75 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9.2M19,662 at $468.57 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.4M7,241 at $469.61 | filing |
| 19 Feb 2026filed 23 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3.7M23,479 at $155.57 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Amit Sachdev; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.